Humans; Male; Female; Aged; Aged, 80 and over; Clarithromycin/adverse effects; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use; Cytochrome P-450 CYP3A Inhibitors/adverse effects; Pyrimidines/metabolism; Pyrimidines/therapeutic use; Pyrimidines/pharmacokinetics; Rhabdomyolysis/chemically induced; Sulfonamides/metabolism; Sulfonamides/therapeutic use; Sulfonamides/pharmacokinetics; Fatty Acids, Monounsaturated/metabolism; Fatty Acids, Monounsaturated/therapeutic use; Fatty Acids, Monounsaturated/pharmacokinetics; Pravastatin/metabolism; Pravastatin/therapeutic use; Pravastatin/pharmacokinetics; Hydroxymethylglutaryl-CoA Reductase Inhibitors/metabolism; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent/antagonists & inhibitors; Liver-Specific Organic Anion Transporter 1; Drug Interactions; Acute Kidney Injury/chemically induced; Rosuvastatin Calcium; Fluorobenzenes/metabolism; Fluorobenzenes/therapeutic use; Fluorobenzenes/pharmacokinetics; Solute Carrier Organic Anion Transporter Family Member 1B3; Fluvastatin; Hyperkalemia/chemically induced; Indoles/metabolism; Indoles/therapeutic use; Indoles/pharmacokinetics